Emtora Biosciences

Commercializing eRapa™,
a novel, targeted formulation of rapamycin

In the News

May 1, 2019: Emtora Obtains Major Federal Drug Designation

April 30, 2019: Emtora Turns Sights on Rare Genetic Disease, New Funding

March 22, 2019: Local Biotech Companies Work to Navigate Maze to Market

March 13, 2019: Emtora Biosciences CEO Talks New Name, Focus, and Finish Line

February 28, 2019: Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO

February 26, 2019: San Antonio Biotech Changing its Name and CEO

February 26, 2019: Rapamycin Holdings Changes Name to Emtora Biosciences, Hires New CEO

November 1, 2018: SA Drug Development Company Reaches Major Milestone

May 9, 2018: Rapamycin Holdings Plans Tests of eRapa for Prostate Cancer

October 17, 2017: San Antonio Drug Developer Obtains Key Patent Approval in Path to Market

August 7, 2017: New Rapamycin CEO Hired to Handle Funding, FDA Inflection Points

April 1, 2016: Drug Designed in San Antonio Fights Age-Related Diseases